Andrew Kenneth William Powell is Director at Aclaris Therapeutics, Inc. (ACRS). They have made 10 open-market trades across 6 companies since 2007, most recently 2024-06-01.
CIK 0001304113
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
7 open-market purchases totalling $44K since 2007, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ACRS | BUY | 2024-03-01 | 2024-03-05 | $1.24 | $18K | -11.4% | -6.8% | -21.2% |
| LNDC | BUY | 2019-01-11 | 2019-01-14 | $11.62 | $6K | +5.2% | +1.6% | -12.4% |
| ACRS | BUY | 2018-05-16 | 2018-05-17 | $19.12 | $10K | -9.5% | +0.4% | -20.2% |
| MDVN | SELL | 2016-06-06 | 2016-06-06 | $60.42 | $312K | +0.0% | +5.0% | +36.2% |
| ITMN | SELL · 10b5-1 | 2014-09-02 | 2014-09-03 | $73.47 | $551K | N/A | N/A | N/A |
| ITMN | SELL | 2014-05-29 | 2014-06-03 | $39.44 | $39K | N/A | N/A | N/A |
| CRTX | SELL | 2011-07-15 | 2011-07-18 | $8.63 | $17K | +30.4% | +64.5% | +64.5% |
| CRTX | SELL · 10b5-1 | 2011-04-04 | 2011-04-06 | $6.53 | $13K | +30.4% | +64.5% | +64.5% |
| CRTX | SELL · 10b5-1 | 2011-01-07 | 2011-01-10 | $5.73 | $11K | +30.4% | +64.5% | +64.5% |
| CRTX | SELL · 10b5-1 | 2010-11-01 | 2010-11-02 | $6.28 | $50K | +30.4% | +64.5% | +64.5% |
| CGPI | BUY | 2007-11-28 | 2007-11-30 | $7.30 | $1K | N/A | N/A | N/A |
| CGPI | BUY | 2007-11-16 | 2007-11-20 | $8.01 | $3K | N/A | N/A | N/A |
| CGPI | BUY | 2007-11-08 | 2007-11-13 | $8.47 | $4K | N/A | N/A | N/A |
| CGPI | BUY | 2007-05-22 | 2007-05-24 | $10.48 | $2K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.